Oura Extends Menopause Impact Tool to Health Partners in Phased Rollout

Members can initially connect results with Alloy Health, Oova, Xella, Pomelo and Wisp. Maven, Mira, Hertility, Gennev and Tia are scheduled to follow. The questionnaire tracks reported effects on quality of life and daily functioning across 22 symptoms and seven domains.

The business development is a broader route for sharing those reported results within partner workflows, rather than a new retail hardware launch. Oura says more than 600,000 members have completed the scale since its May launch.

It evaluated the instrument with more than 2,900 participants and submitted the validation manuscript for peer review; submission is not the same as completed peer-reviewed publication. The release presents intended benefits for communication and tracking over time, not evidence that the integrations improve clinical outcomes.

The scale should not be described as a diagnosis or as replacing a clinician’s assessment.